<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Malar J</journal-id><journal-id journal-id-type="iso-abbrev">Malar. J</journal-id><journal-title-group><journal-title>Malaria Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2875</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5848522</article-id><article-id pub-id-type="publisher-id">2252</article-id><article-id pub-id-type="doi">10.1186/s12936-018-2252-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African <italic>Plasmodium falciparum</italic> isolates</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gendrot</surname><given-names>Mathieu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Foguim</surname><given-names>Francis Tsombeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Robert</surname><given-names>Marie Gladys</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Amalvict</surname><given-names>R&#x000e9;my</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mosnier</surname><given-names>Joel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Benoit</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Madamet</surname><given-names>Marylin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pradines</surname><given-names>Bruno</given-names></name><address><email>bruno.pradines@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><collab>the French National Reference Centre for Imported Malaria Study Group<contrib-group><contrib contrib-type="author"><name><surname>Augis</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Basset</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bastien</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Benoit-Vical</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Berry</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brouqui</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cividin</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Delaunay</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Delhaes</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Drancourt</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gaillard</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Genin</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Garnotel</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Javelle</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>L&#x02019;Ollivier</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leveque</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Malvy</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marty</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mechain</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>M&#x000e9;nard</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Millet</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Minodier</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mottard</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Parola</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Piarroux</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pomares-Estran</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Receveur</surname><given-names>M. -C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Robin</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sappa</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Savini</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Simon</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sterkers</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Surcouf</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Varlet</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wolff</surname><given-names>A.</given-names></name></contrib></contrib-group></collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.418221.c</institution-id><institution>Unit&#x000e9; Parasitologie et entomologie, D&#x000e9;partement des maladies infectieuses, </institution><institution>Institut de recherche biom&#x000e9;dicale des arm&#x000e9;es, Institut hospitalo-universitaire (IHU) M&#x000e9;diterran&#x000e9;e Infection, </institution></institution-wrap>19-21 Boulevard Jean Moulin, 13005 Marseille, France </aff><aff id="Aff2"><label>2</label>Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, IHU-M&#x000e9;diterran&#x000e9;e Infection, Marseille, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0519 5986</institution-id><institution-id institution-id-type="GRID">grid.483853.1</institution-id><institution>Centre national de r&#x000e9;f&#x000e9;rence du Paludisme, </institution><institution>Institut hospitalo-universitaire (IHU) M&#x000e9;diterran&#x000e9;e Infection, </institution></institution-wrap>Marseille, France </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>17</volume><elocation-id>108</elocation-id><history><date date-type="received"><day>10</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1"><italic>Plasmodium falciparum</italic> resistance to artemisinin-based combination therapy has emerged and spread in Southeast Asia. In areas where artemisinin resistance is emerging, the efficacy of combination is now based on partner drugs. In this context, the identification of novel markers of resistance is essential to monitor the emergence and spread of resistance to these partner drugs. The ubiquitylation pathway could be a possible target for anti-malarial compounds and might be involved in resistance. Polymorphisms in the E3 ubiquitin-protein ligase (PF3D7_0627300) gene could be associated with decreased in vitro susceptibility to anti-malarial drugs.</p></sec><sec><title>Methods</title><p id="Par2"><italic>Plasmodium falciparum</italic> isolates were collected from patients hospitalized in France with imported malaria from a malaria-endemic country from January 2015 to December 2016 and, more particularly, from African French-speaking countries. In total, 215 isolates were successfully sequenced for the E3 ubiquitin-protein ligase gene and assessed for ex vivo susceptibility to anti-malarial drugs.</p></sec><sec><title>Results</title><p id="Par3">The D113N mutation in the RING E3 ubiquitin-protein ligase gene was present in 147 out of the 215 samples (68.4%). The IC<sub>50</sub> values for the ten anti-malarial drugs were not significantly different between the wild-type and mutant parasites (p values between 0.225 and 0.933). There was no significant difference in terms of the percentage of parasites with decreased susceptibility between the D113 wild-type and the 133N mutated <italic>P. falciparum</italic> strains (p values between 0.541 and 1).</p></sec><sec><title>Conclusion</title><p id="Par4">The present data confirmed the absence of the association between polymorphisms in the RING E3 ubiquitin-protein ligase gene and the ex vivo susceptibility to common anti-malarial drugs in African <italic>P. falciparum</italic> isolates.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Malaria</kwd><kwd><italic>Plasmodium falciparum</italic></kwd><kwd>Anti-malarial drug</kwd><kwd>In vitro</kwd><kwd>Resistance</kwd><kwd>Molecular marker</kwd><kwd>RING E3 ubiquitin-protein ligase gene</kwd></kwd-group><funding-group><award-group><funding-source><institution>Sant&#x000e9; Publique France</institution></funding-source><award-id>CNR Paludisme</award-id><principal-award-recipient><name><surname>Pradines</surname><given-names>Bruno</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005902</institution-id><institution>D&#x000e9;l&#x000e9;gation G&#x000e9;n&#x000e9;rale pour l'Armement</institution></institution-wrap></funding-source><award-id>PDH-2-NRBC-4-B-4101</award-id><principal-award-recipient><name><surname>Pradines</surname><given-names>Bruno</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007356</institution-id><institution>Fondation M&#x000e9;diterran&#x000e9;e Infection</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par20"><italic>Plasmodium falciparum</italic> resistance to most anti-malarial drugs has emerged in Southeast Asia and spread to Africa [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Since 2005, the World Health Organization (WHO) has recommended artemisinin-based combination therapy (ACT) as first-line treatment for uncomplicated malaria and intravenous artesunate for the treatment of severe malaria. However, artemisinin derivative resistant <italic>P. falciparum</italic> strains have emerged in western Cambodia, Myanmar and Thailand and throughout Southeast Asia [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. This resistance has resulted in a delayed parasite clearance in patients treated with artesunate monotherapy or ACT therapy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In areas where artemisinin resistance is emerging, combination efficacy is based now on partner drugs. In this context, the discovery of novel markers of resistance is essential to monitor the emergence and spread of resistance to these partner drugs.</p><p id="Par21">The ubiquitylation pathway is one of the major pathways used by all eukaryotic organisms to regulate protein abundance and protein activities in their cells. The molecular modification of proteins by ubiquitin, called ubiquitylation, is one of the main changes in post-translational events that are essential to most cellular processes. Ubiquitin is a 76-amino-acid polypeptide that is preserved in eukaryotic organisms, including <italic>Plasmodium</italic> spp. A single ubiquitin may bond covalently to a lysine residue on a protein through a complex enzymatic cascade involving activating, conjugating and ligase enzymes. Several ubiquitins can be bound to lysine residues on a single protein. Furthermore, ubiquitins can be bound to each other in polyubiquitin chains. At least four ubiquitins are required to designate the protein to a proteasome. To bind those ubiquitins, a multi-enzyme complex containing an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme and the E3 ubiquitin-protein ligase is involved (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Mechanism of the ubiquitin pathway and the transfer role of the ubiquitin protein ligase E3</p></caption><graphic xlink:href="12936_2018_2252_Fig1_HTML" id="MO1"/></fig></p><p id="Par22">Ubiquitylation begins with the use of ATP by the E1 enzyme to adenylate its carboxyl terminus, allowing a molecule of ubiquitin to be transferred on the E1 enzyme active-site cysteine and resulting in a thioester bond between the E1 enzyme and ubiquitin. Afterward, a trans-thioesterification occurs with the E2 enzyme, which carries out the transfer of the E1 enzyme ubiquitin to a conserved cysteine on the E2 enzyme. In the end, the E3 enzyme removes the E2 bonded ubiquitin to create an isopeptide bond between the C-terminal glycine on ubiquitin and the epsilon-amino group of the lysine residue on the targeted protein. The target substrate is specific to the E3 ligase enzyme. The E3 ligase enzyme must bind at least four residues for proteasome addressing.</p><p id="Par23">Three types of E3 ligase enzymes are described as follows: the homologous to E6-associated protein C-terminus (HECT) ligases, really interesting new gene (RING) fingers and finally, U-box E3 ligases. The latter type of ligase plays a primordial role in substrate specificity.</p><p id="Par24">The ubiquitylation pathway could be a possible target for anti-malarial compounds and might be involved in the resistance of malaria [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Previous publications using a genome-wide association study (GWAS) showed mutations in the E2 ubiquitin-conjugating enzyme gene (PF3D7_1243700) and the HECT E3 ubiquitin ligase gene (PF3D7_0826100) in Senegalese isolates that showed pyrimethamine resistance [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, an HECT E3 ubiquitin ligase gene polymorphism might be involved in quinine- and quinidine-reduced susceptibility [<xref ref-type="bibr" rid="CR14">14</xref>]. Additionally, <italic>P. falciparum</italic> strains carrying the mutant D113N allele for the E3 ubiquitin-protein ligase (PF3D7_0627300) gene were found to be less susceptible in vitro to chloroquine and amodiaquine [<xref ref-type="bibr" rid="CR15">15</xref>]. Ribacke et al. used population genetics approaches to identify genes under positive drug selection. One of them was the RING ubiquitine ligase with the D113N mutation. They proved no difference in growth between parasites bearing the mutation and those which do not, but the mutant strains were less susceptible to CQ and amodiaquine. Parasite clones were then matched in competition experiments with the drugs and those carrying the mutation out-competed the wild types clones, suggesting the involvement of D113N mutation as a major involvement in ubiquitylation cascade and adaptive response to drug pressure. Another study showed no significant association between the D113N mutation and ex vivo reduced susceptibility to most conventional anti-malarial drugs, except a trend with reduced susceptibility to piperaquine in <italic>P. falciparum</italic> Senegalese isolates, but the major limitations of this study was the low number of isolates and the geographical provenance of them [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par25">The objective of the current study was to analyse polymorphisms of the E3 ubiquitin-protein ligase gene (PF3D7_0627300) in <italic>P. falciparum</italic> African isolates, more particularly the D113N mutation and to evaluate the association of this polymorphism with ex vivo susceptibility to chloroquine (CQ), quinine (QN), monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), artesunate (AS) and doxycycline (DOX) to confirm previous data.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and sample collection</title><p id="Par26">In total, 215 <italic>P. falciparum</italic> isolates were successfully sequenced for the E3 ubiquitin-protein ligase gene and assessed for ex vivo susceptibility to anti-malarial drugs. They were collected from patients hospitalized in France with imported malaria from a malaria-endemic country from January 2015 to December 2016 and, more particularly, from African French-speaking countries such as C&#x000f4;te d&#x02019;Ivoire, Cameroon, Central African Republic, Republic of Congo, Guinea, Burkina Faso, Togo, Gabon and Senegal. The samples were sent from different civilian or military hospitals of the French National Reference Centre for Imported Malaria network (Aix en Provence, Bordeaux, Marseille, Montpellier, Nice, Toulon and Toulouse) to the French National Reference Centre for Malaria (IRBA, IHU M&#x000e9;diterran&#x000e9;e Infection Marseille). The parasitaemia, ranging from 0.005 to 9.5%, was estimated on thin blood smears stained by eosin and methylene blue using a RAL<sup>&#x000ae;</sup> kit (R&#x000e9;actifs RAL, Paris, France). The diagnosis of <italic>P. falciparum</italic> mono-infection was confirmed by real-time PCR (LightCycler 2.0, Roche Group, Switzerland) as previously described [<xref ref-type="bibr" rid="CR17">17</xref>].</p></sec><sec id="Sec4"><title>Drugs</title><p id="Par27">CQ, QN, DHA and DOX were obtained from Sigma (Saint Louis, MO, USA). DQ was from the WHO (Geneva, Switzerland), and MQ was purchased from Roche (Paris, France). LMF was from Novartis Pharma (Basel, Switzerland), and AS, PPQ and PND were from Shin Poong Pharm Co. (Seoul, Korea). QN, DQ, MQ, DHA, AS, PPQ and DOX were first dissolved in methanol and then diluted in water to final concentrations that ranged from 6 to 3149&#x000a0;nM for QN; 1.9 to 1988&#x000a0;nM for DQ; 1.5 to 392&#x000a0;nM for MQ; 0.1 to 107&#x000a0;nM for DHA and AS; 1.9 to 998&#x000a0;nM for PPQ and 0.5 to 497&#x000a0;&#x000b5;M for DOX. CQ and PND were resuspended and diluted in water to final concentrations ranging from 6 to 3231&#x000a0;nM and 0.4 to 199&#x000a0;nM, respectively. LMF was resuspended and diluted in ethanol to obtain final concentrations ranging from 0.6 to 310&#x000a0;nM.</p></sec><sec id="Sec5"><title>Ex vivo assay</title><p id="Par28">The susceptibility of the 215 isolates to the ten anti-malarial drugs was assessed without culture adaptation. A total of 100&#x000a0;&#x000b5;L of parasitized erythrocytes (final parasitaemia at 0.5% and a final haematocrit at 1.5%) was aliquoted into 96-well plates that were pre-dosed with a concentration gradient of anti-malarial drugs (CQ, QN, MQ, DQ, LMF, DHA, AS, PPQ, PND and DOX). The plates were incubated for 72&#x000a0;h in controlled atmosphere at 85% N<sub>2</sub>, 10% O<sub>2</sub>, 5% CO<sub>2</sub> and 37&#x000a0;&#x000b0;C. The drug susceptibility assay was done using the HRP2 ELISA-based assay Malaria Ag Celisa kit (ref KM2159, Cellabs PTY LDT, Brookvale, Australia) as previously described [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par29">Each batch of plates was validated using the CQ-resistant W2 strain (isolated in Indochina; obtained from MR4, VA, USA) in four independent experiments using the same conditions described below. The mean 50% inhibitory concentration (IC<sub>50</sub>) values for the chloroquine-resistant W2 strain for the different batches used over 2&#x000a0;years were 484&#x02009;&#x000b1;&#x02009;40&#x000a0;nM for CQ, 388&#x02009;&#x000b1;&#x02009;29&#x000a0;nM for QN, 97&#x02009;&#x000b1;&#x02009;18&#x000a0;nM for DQ, 1.0&#x02009;&#x000b1;&#x02009;0.4&#x000a0;nM for LMF, 26.3&#x02009;&#x000b1;&#x02009;3.1&#x000a0;nM for MQ, 54.1&#x02009;&#x000b1;&#x02009;5.4&#x000a0;nM for PPQ, 20.4&#x02009;&#x000b1;&#x02009;3.4&#x000a0;nM for PND, 2.5&#x02009;&#x000b1;&#x02009;0.4&#x000a0;nM for DHA, 1.5&#x02009;&#x000b1;&#x02009;0.3&#x000a0;nM for AS and 11.5&#x02009;&#x000b1;&#x02009;1.9&#x000a0;&#x000b5;M for DOX. A comparison of the W2 susceptibility data of the ten anti-malarial drugs between the different batches of plates indicated that there was no significant difference in the responses to antimalarial drugs over the 2&#x000a0;years (0.583&#x02009;&#x0003c;&#x02009;p&#x02009;&#x0003c;&#x02009;0.993). The polymorphic genetic markers <italic>msp1</italic> and <italic>msp2</italic> and microsatellite markers specific to <italic>P. falciparum</italic> were genotyped at least once a month to verify W2 clonality [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par30">The cut-off values for the reduced in vitro susceptibility or resistance were as follows: 100&#x000a0;nM (CQ), 800&#x000a0;nM (QN), 80&#x000a0;nM (DQ), 30&#x000a0;nM (MQ), 150&#x000a0;nM (LMF), 135&#x000a0;nM (PPQ), 60&#x000a0;nM (PND), 10.5&#x000a0;nM (DHA and AS) and 35&#x000a0;&#x000b5;M (DOX) [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec6"><title>Gene sequence polymorphism analysis</title><p id="Par31">The total genomic DNA of each isolate was isolated using the QIAamp DNA Blood Mini Kit according to the manufacturer&#x02019;s recommendations (Qiagen, Germany). The E3 ubiquitin-protein ligase gene (PF3D7_0627300) is a 1349&#x000a0;bp gene whose the -5&#x02032; end region was amplified by PCR using the following primer pairs: 5&#x02032;-AAT-GGT-CCA-GAA-GAA-GAT-TAT-3&#x02032; and 5&#x02032;-ATT-TCG-AAT-TAT-CTT-CTA-CAT-C-3&#x02032;. The -3&#x02032; region was not sequenced because the objective of the study focused on the previous findings concerning the D113N mutation only [<xref ref-type="bibr" rid="CR15">15</xref>]. The reaction mixture contained 200&#x000a0;ng of genomic DNA, 0.32&#x000a0;&#x000b5;M of each primer, 1&#x000d7; final of reaction buffer (750&#x000a0;mM of Tris&#x02013;HCl, 200&#x000a0;mM of (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.1% (v/v) Tween 20 and stabilizer, pH 8.8), 2.5&#x000a0;mM of MgCl<sub>2</sub>, 200&#x000a0;&#x000b5;M of dNTP mixture and 0.2&#x000a0;U of Hot Diamond Taq<sup>&#x000ae;</sup> polymerase (Eurogentec) in a final volume of 25&#x000a0;&#x000b5;L. The thermal cycler (T3 Biometra) was programmed as follows: 10&#x000a0;min at 95&#x000a0;&#x000b0;C, then 40 cycles of 30&#x000a0;s at 95&#x000a0;&#x000b0;C, 45&#x000a0;s at 45&#x000a0;&#x000b0;C, 90&#x000a0;s at 72&#x000a0;&#x000b0;C and a final extension step of 10&#x000a0;min at 72&#x000a0;&#x000b0;C. The purified amplicons were sequenced using PCR primers and the sequencing primer 5&#x02032;-AAT-ACT-TAT-GAT-ATG-ACA-AGT-GA-3&#x02032; on an ABI Prism 3100 analyser (Applied Biosystems) according to the manufacturers&#x02019; instructions. The sequences were analysed using BioEdit, version 7 (Ionis Pharmaceuticals, California, USA) to identify the D113N mutation.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par32">All the statistical studies, dot plots and the Africa map were created using the R software (R Core Team, Vienna, Austria).</p></sec></sec><sec id="Sec8"><title>Results and discussion</title><p id="Par33">The IC<sub>50</sub> of the 215 isolates ranged from 6.27 to 500.6&#x000a0;nM for CQ, 5.29 to 690.11&#x000a0;nM for QN, 1.9 to 196.43&#x000a0;nM for DQ, 0.33 to 6.96&#x000a0;nM for LMF, 2.4 to 173.43&#x000a0;nM for MQ, 7.5 to 128.7&#x000a0;nM for PPQ, 0.8 to 122.96&#x000a0;nM for PND, 0.09 to 28.11&#x000a0;nM for DHA, 0.1 to 19&#x000a0;nM for AS and 0.46 to 44.89&#x000a0;&#x000b5;M for DOX. The global distribution of <italic>P. falciparum</italic> isolates IC<sub>50</sub> is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Dot plot of the IC<sub>50</sub> total distribution of each <italic>Plasmodium falciparum</italic> isolate for chloroquine (CQ), quinine (QN), monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), artesunate (AS) and doxycycline (DOX). Each dot is for an IC<sub>50</sub> isolate, blue dots represent the wild D113 isolates and red dots the mutant 113N isolates. The black bar indicates the threshold for parasites with reduced susceptibility</p></caption><graphic xlink:href="12936_2018_2252_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par34">Among the 215 isolates, 65.9% of the parasites showed reduced ex vivo susceptibility to MQ, 32.7% to CQ, 19,3% to DOX, 16,3% of DHA, 9.0% of DQ, 8,4% to AS and 4,7% to PND. The data concerning the decrease of the susceptibility to DHA and AS should be analysed with caution. The IC<sub>50</sub> were estimated by a standard ex vivo test. Ring-stage survival assay (RSA), which is a better indicator of in vitro artemisinin resistance, should have been performed. Clinical resistance to artemisinin was manifested by an increase in the ring-stage survival rate after contact with artemisinin [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par35">The D113N mutation of the RING E3 ubiquitin-protein ligase gene was present in 147 of the 215 samples (68.4%). The repartition of the D113N mutation per countries of origin is presented in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. The D113N mutation was present in 69.6% of the isolates collected in 2015 (78 out of 112) and 66.9% in 2016 (69 out of 103). There was no significant difference between the 2&#x000a0;years and the proportion of mutant 113N isolates (p value&#x02009;=&#x02009;0.7854, Chi squared test with Yates continuity correction).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Repartition of the D113N mutation per its country of origin. The percentage of the D113N mutation in the E3 ubiquitin protein ligase gene (green to red coloration)</p></caption><graphic xlink:href="12936_2018_2252_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par36">A new mutation, E237D, was identified in a single isolate and conformed twice. This isolate showed the following IC<sub>50</sub>: 10.3&#x000a0;nM for PPQ, 28.7&#x000a0;nM for CQ, 121.4&#x000a0;nM for QN, 8.9&#x000a0;nM for DQ, 0.6&#x000a0;nM for LMF, 21.6&#x000a0;nM for MQ, 5.2&#x000a0;nM for PND, 5.3&#x000a0;nM for DHA, 5.8&#x000a0;nM for AS and 21.6&#x000a0;&#x000b5;M for DOX. This mutant parasite was susceptible to all the anti-malarial drugs tested.</p><p id="Par37">The IC<sub>50</sub> values for the ten anti-malarial drugs were not significantly different between the wild-type and mutant parasites (p values between 0.225 and 0.933) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The distribution of the IC<sub>50</sub> values for the ten anti-malarial drugs is presented in blue in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> for the D113 wild-type parasites and in red for the 113N mutant parasites.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Ex vivo susceptibilities of 215 African <italic>Plasmodium falciparum</italic> isolates to chloroquine (CQ), quinine (QN), monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), artesunate (AS) and doxycycline (DOX) according to the D113N mutation in the RING E3 ubiquitin protein ligase (PF3D7_0627300) gene</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Drug</th><th align="left" colspan="2">Wild-type D113 (31.6%)</th><th align="left" colspan="2">Mutated 113N (68.4%)</th><th align="left" rowspan="2">p value<sup>c</sup></th></tr><tr><th align="left">Mean IC<sub arrange="stack">50</sub><sup arrange="stack">a</sup></th><th align="left">Min and max<sup>b</sup></th><th align="left">Mean IC<sub>50</sub></th><th align="left">Min and max<sup>b</sup></th></tr></thead><tbody><tr><td align="left">CQ</td><td char="." align="char">75.5</td><td align="left">[6.3&#x02013;791.6]</td><td char="." align="char">75.1</td><td align="left">[11.7&#x02013;615.9]</td><td char="." align="char">0.933</td></tr><tr><td align="left">QN</td><td char="." align="char">128.2</td><td align="left">[5.3&#x02013;631]</td><td char="." align="char">124.8</td><td align="left">[9.5&#x02013;690.1]</td><td char="." align="char">0.824</td></tr><tr><td align="left">DQ</td><td char="." align="char">30.3</td><td align="left">[1.9&#x02013;251.5]</td><td char="." align="char">30.4</td><td align="left">[6.3&#x02013;196.4]</td><td char="." align="char">0.830</td></tr><tr><td align="left">MQ</td><td char="." align="char">32.9</td><td align="left">[5.5&#x02013;173.4]</td><td char="." align="char">40.2</td><td align="left">[2.4&#x02013;172.6]</td><td char="." align="char">0.225</td></tr><tr><td align="left">LMF</td><td char="." align="char">1.33</td><td align="left">[0.4&#x02013;15.1]</td><td char="." align="char">1.35</td><td align="left">[0.33&#x02013;16.7]</td><td char="." align="char">0.532</td></tr><tr><td align="left">PPQ</td><td char="." align="char">31.9</td><td align="left">[6.8&#x02013;128.7]</td><td char="." align="char">34.0</td><td align="left">[7.5&#x02013;127.5]</td><td char="." align="char">0.398</td></tr><tr><td align="left">PND</td><td char="." align="char">17.1</td><td align="left">[1.67&#x02013;89.2]</td><td char="." align="char">15.7</td><td align="left">[0.8&#x02013;123.0]</td><td char="." align="char">0.896</td></tr><tr><td align="left">DHA</td><td char="." align="char">4.02</td><td align="left">[0.09&#x02013;21.1]</td><td char="." align="char">3.90</td><td align="left">[0.2&#x02013;28.1]</td><td char="." align="char">0.646</td></tr><tr><td align="left">ASU</td><td char="." align="char">3.64</td><td align="left">[0.21&#x02013;23.6]</td><td char="." align="char">3.57</td><td align="left">[0.1&#x02013;21.2]</td><td char="." align="char">0.851</td></tr><tr><td align="left">DOX</td><td char="." align="char">16.8</td><td align="left">[0.46&#x02013;51.1]</td><td char="." align="char">16.4</td><td align="left">[0.79&#x02013;49.9]</td><td char="." align="char">0.463</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Geometric mean inhibitory concentration 50%</p><p><sup>b</sup>Minimum and maximum value for each drug</p><p><sup>c</sup>p values were determined by the Student t test test</p></table-wrap-foot></table-wrap>
</p><p id="Par38">The isolates were categorized as susceptible or presenting ex vivo reduced susceptibility to the different anti-malarial drugs. There was no significant difference between the proportion of D113 wild-type parasites and 113N mutated parasites showing reduced ex vivo susceptibility to the different drugs used (p values between 0.541 and 1) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Comparison of the prevalences of <italic>Plasmodium falciparum</italic> isolates with reduced susceptibility to chloroquine (CQ), quinine (QN), monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), artesunate (AS) and doxycycline (DOX) according to the D113N mutation in the E3 ubiquitin protein ligase gene. p values were determined using Fisher&#x02019;s exact test</p></caption><graphic xlink:href="12936_2018_2252_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par39">Polymorphisms of the RING E3 ubiquitin-protein ligase gene seem to be uniformly distributed, regardless of the African origin of the <italic>P. falciparum</italic> isolates. Among the 215 isolates, 52 came from Cameroon, and 41 were from C&#x000f4;te d&#x02019;Ivoire. The parasites were mutant in 65 and 66% of the isolates, respectively. Countries with a low number of collected samples ranging from 1 to 10 showed a mean of 66.9% of mutant parasites. Countries with a number of collected isolates above 10 (except Cameroon and C&#x000f4;te d&#x02019;Ivoire) showed a mean of 74% for the 113N mutant strains.</p><p id="Par40">The emergence of resistance to ACT in Southeast Asia [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], even to the most recently commercialized DHA-PPQ in Cambodia [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], requires the identification of new molecular markers of resistance to ACT partner drugs for monitoring the emergence and spread of resistance.</p><p id="Par41">Previous studies showed that <italic>P. falciparum</italic> strains carrying the 113N mutant allele for the E3 ubiquitin-protein ligase gene were less susceptible ex vivo to CQ and DQ, and that all the Senegalese isolates with reduced susceptibility to PPQ were mutants [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Although the D113N mutation was found in a large number of samples (n&#x02009;=&#x02009;147, 68.4%), this mutation was not found to be involved in the susceptibility modulation to common anti-malarial drugs. The distribution of the IC<sub>50</sub> values for all ten anti-malarial drugs tested did not show a significant difference between the D113 wild-type and 113N mutant groups. The decrease in the ex vivo susceptibility to CQ and DQ previously observed in genetically modified parasites was not found in these field African isolates [<xref ref-type="bibr" rid="CR15">15</xref>]. This could be explained by the use of cloned parasites in the study of Ribacke et al., while African field isolates were assessed in the present study. The difference between clones and field parasites may induce differences between in vitro development of mutations and reduced susceptibility and wild isolates showing different patterns of gene sequence regulation and expression. There was no significant difference in the proportion of parasites with decreased susceptibility to PPQ between the D113 wild-type and the mutated 113N <italic>P. falciparum</italic> strains in contrary to previous findings [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec9"><title>Conclusion</title><p id="Par42">The ubiquitylation pathway, a key in post-translational regulation in eukaryotes, could be a possible target for anti-malarial compounds [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, the present data confirmed the absence of an association between polymorphisms in the RING E3 ubiquitin-protein ligase gene and the ex vivo susceptibility to common anti-malarial drugs in African <italic>P. falciparum</italic> isolates.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACT</term><def><p id="Par5">artemisinin-based combination therapy</p></def></def-item><def-item><term>AS</term><def><p id="Par6">artesunate</p></def></def-item><def-item><term>CQ</term><def><p id="Par7">chloroquine</p></def></def-item><def-item><term>DHA</term><def><p id="Par8">dihydroartemisinin</p></def></def-item><def-item><term>DNA</term><def><p id="Par9">deoxyribonucleic acid</p></def></def-item><def-item><term>DQ</term><def><p id="Par10">monodesethylamodiaquine</p></def></def-item><def-item><term>Dox</term><def><p id="Par11">doxycycline</p></def></def-item><def-item><term>HECT</term><def><p id="Par12">homologous to E6-associated protein C-terminus ligases</p></def></def-item><def-item><term>LMF</term><def><p id="Par13">lumefantrine</p></def></def-item><def-item><term>MQ</term><def><p id="Par14">mefloquine</p></def></def-item><def-item><term>PND</term><def><p id="Par15">pyronaridine</p></def></def-item><def-item><term>PPQ</term><def><p id="Par16">piperaquine</p></def></def-item><def-item><term>QN</term><def><p id="Par17">quinine</p></def></def-item><def-item><term>RING</term><def><p id="Par18">really interesting new gene</p></def></def-item><def-item><term>WHO</term><def><p id="Par19">World Health Organization</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>MG, FTF, MGR and MM carried out the molecular studies. RA, JM, NB and BP carried out the ex vivo evaluation of anti-malarial drug susceptibility. BP and MM conceived of and coordinated the study. MG, MM and BP analysed the data and drafted the manuscript. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par43">The authors thank the patients and the staff of the hospitals of the French National Reference Centre for Imported Malaria network.</p></sec><sec id="FPar2"><title>French National Reference Centre for Imported Malaria Study Group</title><p id="Par44">V. Augis (H&#x000f4;pital Pellegrin, Bordeaux), D. Basset (Centre Hospitalier Universitaire de Montpellier, Montpellier), P. Bastien (Centre Hospitalier Universitaire de Montpellier, Montpellier), F. Benoit-Vical (Centre Hospitalier Universitaire de Rangueil, Toulouse), A. Berry (Centre Hospitalier Universitaire de Rangueil, Toulouse), P. Brouqui (Institut Hospitalo-Universitaire M&#x000e9;diterran&#x000e9;e Infection, Marseille), M. Cividin (Centre Hospitalier du Pays d&#x02019;Aix, Aix en Provence), P. Delaunay (Centre Hospitalier Universitaire de l&#x02019;Archet, Nice), L. Delhaes (H&#x000f4;pital Pellegrin, Bordeaux), M. Drancourt (Institut Hospitalo-Universitaire M&#x000e9;diterran&#x000e9;e Infection, Marseille), T. Gaillard (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Saint-Anne, Toulon), A. Genin (Centre Hospitalier du Pays d&#x02019;Aix, Aix en Provence), E. Garnotel (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Laveran, Marseille), E. Javelle (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Laveran, Marseille), C. L&#x02019;Ollivier (Institut Hospitalo-Universitaire M&#x000e9;diterran&#x000e9;e Infection, Marseille), M. Leveque (Centre Hospitalier Universitaire de Montpellier, Montpellier), D. Malvy (H&#x000f4;pital Pellegrin, Bordeaux), P. Marty (Centre Hospitalier Universitaire de l&#x02019;Archet, Nice), M. Mechain (H&#x000f4;pital Pellegrin, Bordeaux), G. M&#x000e9;nard (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Saint-Anne, Toulon), P. Millet (H&#x000f4;pital Pellegrin, Bordeaux), P. Minodier (H&#x000f4;pital Nord, Marseille), A. Mottard (H&#x000f4;pital de Fr&#x000e9;jus-Saint Raphael, Fr&#x000e9;jus), P. Parola (Institut Hospitalo-Universitaire M&#x000e9;diterran&#x000e9;e Infection, Marseille), R. Piarroux (H&#x000f4;pital la Timone, Marseille), C. Pomares-Estran (Centre Hospitalier Universitaire de l&#x02019;Archet, Nice), M.-C. Receveur (H&#x000f4;pital Pellegrin, Bordeaux), A. Robin (Centre Hospitalier du Pays d&#x02019;Aix, Aix en Provence), E. Sappa (Centre Hospitalier du Pays d&#x02019;Aix, Aix en Provence), H. Savini (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Laveran, Marseille), F. Simon (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Laveran, Marseille), Y. Sterkers (Centre Hospitalier Universitaire de Montpellier, Montpellier), C. Surcouf (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Laveran, Marseille), E. Varlet (Centre Hospitalier Universitaire de Montpellier, Montpellier), A. Wolff (H&#x000f4;pital d&#x02019;Instruction des Arm&#x000e9;es Laveran, Marseille).</p></sec><sec id="FPar3"><title>Competing interests</title><p id="Par45">The authors declare that they have no competing interests.</p></sec><sec id="FPar4"><title>Availability of data and materials</title><p id="Par46">The datasets analysed in this study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par47">Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p id="Par48">Bio-banking of human clinical samples used for malaria diagnostics and secondary uses for scientific purposes is possible as long as the corresponding patients are informed and have not indicated any objections. This requirement was fulfilled here by giving verbal information to the patients, and no immediate or delayed patient opposition was reported to the hospital clinicians. Informed consent was not required for this study because the sampling procedures and testing are part of the French national recommendations for the care and surveillance of malaria.</p></sec><sec id="FPar7"><title>Funding</title><p id="Par49">This research was supported by the French Institute for Public Health Surveillance (Sant&#x000e9; Publique France, Grant CNR paludisme) and the D&#x000e9;l&#x000e9;gation G&#x000e9;n&#x000e9;rale pour l&#x02019;Armement (Grant No. PDH-2-NRBC-4-B-4104). Francis T Foguim was supported by a scholarship from the Foundation M&#x000e9;diterran&#x000e9;e Infection.</p></sec><sec id="FPar8"><title>Publisher&#x02019;s Note</title><p id="Par50">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Venkatesan</surname><given-names>M</given-names></name><name><surname>Ohashi</surname><given-names>J</given-names></name><name><surname>Culleton</surname><given-names>R</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Tsukahara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Limited geographical origin and global spread of sulfadoxine-resistant <italic>dhps</italic> alleles in <italic>Plasmodium falciparum</italic> populations</article-title><source>J Infect Dis</source><year>2011</year><volume>204</volume><fpage>1980</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir664</pub-id><?supplied-pmid 22021623?><pub-id pub-id-type="pmid">22021623</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootton</surname><given-names>JC</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Ferdig</surname><given-names>MT</given-names></name><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Baruch</surname><given-names>DI</given-names></name><etal/></person-group><article-title>Genetic diversity and chloroquine selective sweeps in <italic>Plasmodium falciparum</italic></article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>320</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1038/nature00813</pub-id><?supplied-pmid 12124623?><pub-id pub-id-type="pmid">12124623</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dondorp</surname><given-names>AM</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>D</given-names></name><name><surname>Phyo</surname><given-names>AP</given-names></name><name><surname>Tarning</surname><given-names>J</given-names></name><etal/></person-group><article-title>Artemisinin resistance in <italic>Plasmodium falciparum</italic> malaria</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>455</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0808859</pub-id><?supplied-pmid 19641202?><pub-id pub-id-type="pmid">19641202</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Dhorda</surname><given-names>M</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Spread of artemisinin resistance in <italic>Plasmodium falciparum</italic> malaria</article-title><source>N Engl J Med</source><year>2015</year><volume>371</volume><fpage>411</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1314981</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spring</surname><given-names>MD</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Manning</surname><given-names>JE</given-names></name><name><surname>Vanachayangkul</surname><given-names>P</given-names></name><name><surname>Somethy</surname><given-names>S</given-names></name><name><surname>Bun</surname><given-names>R</given-names></name><etal/></person-group><article-title>Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study</article-title><source>Lancet Infect Dis</source><year>2015</year><volume>15</volume><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)70049-6</pub-id><?supplied-pmid 25877962?><pub-id pub-id-type="pmid">25877962</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Suon</surname><given-names>S</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>S</given-names></name><name><surname>Sopha</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dihydroartemisinin-piperaquine resistance in <italic>Plasmodium falciparum</italic> malaria in Cambodia: a multisite prospective cohort study</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00487-9</pub-id><?supplied-pmid 26774243?><pub-id pub-id-type="pmid">26774243</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phuc</surname><given-names>BQ</given-names></name><name><surname>Rasmussen</surname><given-names>C</given-names></name><name><surname>Duong</surname><given-names>TT</given-names></name><name><surname>Dong</surname><given-names>LT</given-names></name><name><surname>Loi</surname><given-names>MA</given-names></name><name><surname>M&#x000e9;nard</surname><given-names>D</given-names></name><etal/></person-group><article-title>Treatment failure of dihydroartemisinin/piperaquine for <italic>Plasmodium falciparum</italic> malaria, Vietnam</article-title><source>Emerg Infect Dis</source><year>2017</year><volume>23</volume><fpage>715</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.3201/eid2304.161872</pub-id><?supplied-pmid 28322709?><pub-id pub-id-type="pmid">28322709</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanh</surname><given-names>NV</given-names></name><name><surname>Thuy-Nhien</surname><given-names>N</given-names></name><name><surname>Tuyen</surname><given-names>NT</given-names></name><name><surname>Tong</surname><given-names>NT</given-names></name><name><surname>Nha-Ca</surname><given-names>NT</given-names></name><name><surname>Dong</surname><given-names>LT</given-names></name><etal/></person-group><article-title>Rapid decline in the susceptibility of <italic>Plasmodium falciparum</italic> to dihydroartemisinin-piperaquine in the south of Vietnam</article-title><source>Malar J</source><year>2017</year><volume>16</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/s12936-017-1680-8</pub-id><?supplied-pmid 28086775?><pub-id pub-id-type="pmid">28086775</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><article-title>The ubiquitin system</article-title><source>Ann RevBiochem</source><year>1998</year><volume>67</volume><fpage>425</fpage><lpage>479</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winklhofer</surname><given-names>KF</given-names></name></person-group><article-title>Parkin and mitochondrial quality control: toward assembling the puzzle</article-title><source>Trends Cell Biol</source><year>2014</year><volume>24</volume><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2014.01.001</pub-id><?supplied-pmid 24485851?><pub-id pub-id-type="pmid">24485851</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Le Roch</surname><given-names>KG</given-names></name></person-group><article-title>The ubiquitin system: an essential component to unlocking the secrets of malaria parasite biology</article-title><source>Mol Biosyst</source><year>2014</year><volume>10</volume><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1039/C3MB70506D</pub-id><?supplied-pmid 24481176?><pub-id pub-id-type="pmid">24481176</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkman</surname><given-names>SK</given-names></name><name><surname>Neafsey</surname><given-names>DE</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Park</surname><given-names>DJ</given-names></name><name><surname>Wirth</surname><given-names>DF</given-names></name></person-group><article-title>Harnessing genomics and genome biology to understand malaria biology</article-title><source>Nat Rev Genet</source><year>2012</year><volume>13</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nrg3187</pub-id><?supplied-pmid 22495435?><pub-id pub-id-type="pmid">22495435</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>DJ</given-names></name><name><surname>Lukens</surname><given-names>AK</given-names></name><name><surname>Neafsey</surname><given-names>DE</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Chang</surname><given-names>HH</given-names></name><name><surname>Valim</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sequence-based association and selection scans identify drug resistance loci in the <italic>Plasmodium falciparum</italic> malaria parasite</article-title><source>Proc Natl Acad Sci USA</source><year>2012</year><volume>109</volume><fpage>13052</fpage><lpage>13057</lpage><pub-id pub-id-type="doi">10.1073/pnas.1210585109</pub-id><?supplied-pmid 22826220?><pub-id pub-id-type="pmid">22826220</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>CP</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Mayer</surname><given-names>S</given-names></name><name><surname>Nurhasanah</surname><given-names>A</given-names></name><name><surname>Cyrklaff</surname><given-names>M</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><etal/></person-group><article-title>A HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in <italic>Plasmodium falciparum</italic></article-title><source>PLoS Genet</source><year>2014</year><volume>10</volume><fpage>1004382</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1004382</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Ribacke U, Martlett M, Patel SD, Seneratne N, Park DJ, Duraisingh M, et al. Adaptative evolution of a ring ubiquitin ligase mediates reduced drug sensitivity in <italic>Plasmodium falciparum</italic>. In: 61st Meeting of American Society of Tropical Medicine and Hygiene. Atlanta, USA, 2012, November 11&#x02013;15, p. 299.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendrot</surname><given-names>M</given-names></name><name><surname>Fall</surname><given-names>B</given-names></name><name><surname>Madamet</surname><given-names>M</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><name><surname>Wade</surname><given-names>KA</given-names></name><name><surname>Amalvict</surname><given-names>R</given-names></name><etal/></person-group><article-title>Absence of association between polymorphisms in the RING E3 ubiquitin protein ligase gene and ex vivo susceptibility to conventional antimalarial drugs in <italic>Plasmodium falciparum</italic> isolates from Dakar, Senegal</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>5010</fpage><lpage>5013</lpage><pub-id pub-id-type="doi">10.1128/AAC.03105-15</pub-id><?supplied-pmid 27185795?><pub-id pub-id-type="pmid">27185795</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurtz</surname><given-names>N</given-names></name><name><surname>Fall</surname><given-names>B</given-names></name><name><surname>Bui</surname><given-names>K</given-names></name><name><surname>Pascual</surname><given-names>A</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><name><surname>Camara</surname><given-names>C</given-names></name><etal/></person-group><article-title><italic>Pfhrp2</italic> and <italic>pfhrp3</italic> polymorphisms in <italic>Plasmodium falciparum</italic> isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests</article-title><source>Malar J</source><year>2013</year><volume>12</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-12-34</pub-id><?supplied-pmid 23347727?><pub-id pub-id-type="pmid">23347727</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fall</surname><given-names>B</given-names></name><name><surname>Madamet</surname><given-names>M</given-names></name><name><surname>Camara</surname><given-names>C</given-names></name><name><surname>Amalvict</surname><given-names>R</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><name><surname>Nakoulima</surname><given-names>M</given-names></name><etal/></person-group><article-title><italic>Plasmodium falciparum</italic> in vitro resistance to monodesethylamodiaquine, Dakar, Senegal, 2014</article-title><source>Emerg Infect Dis</source><year>2016</year><volume>22</volume><fpage>841</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.3201/eid2205.151321</pub-id><?supplied-pmid 27088703?><pub-id pub-id-type="pmid">27088703</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogreau</surname><given-names>H</given-names></name><name><surname>Renaud</surname><given-names>F</given-names></name><name><surname>Bouchiba</surname><given-names>H</given-names></name><name><surname>Durand</surname><given-names>P</given-names></name><name><surname>Assi</surname><given-names>SB</given-names></name><name><surname>Henry</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Genetic diversity and structure of African <italic>Plasmodium falciparum</italic> populations in urban and rural areas</article-title><source>Am J Trop Med Hyg</source><year>2006</year><volume>74</volume><fpage>953</fpage><lpage>959</lpage><?supplied-pmid 16760503?><pub-id pub-id-type="pmid">16760503</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>M</given-names></name><name><surname>Diallo</surname><given-names>I</given-names></name><name><surname>Bordes</surname><given-names>J</given-names></name><name><surname>Ka</surname><given-names>S</given-names></name><name><surname>Pradines</surname><given-names>B</given-names></name><name><surname>Diatta</surname><given-names>B</given-names></name><etal/></person-group><article-title>Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of <italic>Plasmodium falciparum</italic> isolates</article-title><source>Am J Trop Med Hyg</source><year>2006</year><volume>75</volume><fpage>146</fpage><lpage>151</lpage><?supplied-pmid 16837722?><pub-id pub-id-type="pmid">16837722</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradines</surname><given-names>B</given-names></name><name><surname>Bertaux</surname><given-names>L</given-names></name><name><surname>Pomares</surname><given-names>C</given-names></name><name><surname>Delaunay</surname><given-names>P</given-names></name><name><surname>Marty</surname><given-names>P</given-names></name></person-group><article-title>Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveler returning from South-East Asia</article-title><source>Malar J</source><year>2011</year><volume>10</volume><fpage>268</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-10-268</pub-id><?supplied-pmid 21923936?><pub-id pub-id-type="pmid">21923936</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>A</given-names></name><name><surname>Madamet</surname><given-names>M</given-names></name><name><surname>Briolant</surname><given-names>S</given-names></name><name><surname>Gaillard</surname><given-names>T</given-names></name><name><surname>Amalvict</surname><given-names>R</given-names></name><name><surname>Benoit</surname><given-names>N</given-names></name><etal/></person-group><article-title>Multinormal in vitro distribution of <italic>Plasmodium falciparum</italic> susceptibility to piperaquine and pyronaridine</article-title><source>Malar J</source><year>2015</year><volume>14</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s12936-015-0586-6</pub-id><?supplied-pmid 25848972?><pub-id pub-id-type="pmid">25848972</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkowski</surname><given-names>B</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Khim</surname><given-names>N</given-names></name><name><surname>Sreng</surname><given-names>S</given-names></name><name><surname>Chim</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group><article-title>Novel phenotypic assays for the detection of artemisinin-resistant <italic>Plasmodium falciparum</italic> malaria in Cambodia: in vitro and ex vivo drug-response studies</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70252-4</pub-id><?supplied-pmid 24035558?><pub-id pub-id-type="pmid">24035558</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariey</surname><given-names>F</given-names></name><name><surname>Witkowsky</surname><given-names>B</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Beghain</surname><given-names>J</given-names></name><name><surname>Langlois</surname><given-names>AC</given-names></name><name><surname>Khim</surname><given-names>N</given-names></name><etal/></person-group><article-title>A molecular marker of artemisinin-resistant <italic>Plasmodium falciparum</italic> malaria</article-title><source>Nature</source><year>2014</year><volume>505</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/nature12876</pub-id><?supplied-pmid 24352242?><pub-id pub-id-type="pmid">24352242</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Witkowski</surname><given-names>B</given-names></name><name><surname>Khim</surname><given-names>N</given-names></name><name><surname>Menard</surname><given-names>D</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name></person-group><article-title>Artemisinin resistance in <italic>Plasmodium falciparum</italic></article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><fpage>449</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70777-7</pub-id><?supplied-pmid 24849722?><pub-id pub-id-type="pmid">24849722</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponts</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>DW</given-names></name><name><surname>Prudhomme</surname><given-names>J</given-names></name><name><surname>Girke</surname><given-names>T</given-names></name><name><surname>Horrocks</surname><given-names>P</given-names></name><etal/></person-group><article-title>Deciphering the ubiquitin-mediated pathway in apicomplexan parasites: a potential strategy to interfere with parasite virulence</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><fpage>e2386</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0002386</pub-id><?supplied-pmid 18545708?><pub-id pub-id-type="pmid">18545708</pub-id></element-citation></ref></ref-list></back></article>